NOCIL Ltd
NOCILNOCIL Ltd's price has outrun its earnings. −9.0% in a year against EPS −45.9% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −9.0% in a year while annual EPS moved −45.9% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is topping out (3 weeks in) while the P/E sits at the 100th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −19.0% year on year, and 164% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
NOCIL Ltd trades at ₹164, losing momentum at the top and 3 weeks into that stage. That is −2.7% against its own 200-day average. It sits at 60% of a 52-week range of ₹128 to ₹188. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is losing momentum at the top — week 3 of stage 3, confirmed. At ₹164 it trades −2.7% versus its 200-day average and sits at 60% of its 52-week range (₹128–₹188).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +264% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
NOCIL Ltd trades at 59.6× P/E, about the priciest it has ever traded. Its long-run median P/E is 24.7×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 59.6× is about the priciest it has ever traded, against a long-run median of 24.7× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −45.9% against a −9.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −8.9%/yr price move, ~−12.1%/yr came from earnings growth and ~+3.2 pp from the multiple (expanding); over 10y, of the +11.2%/yr price move, ~−5.5%/yr came from earnings growth and ~+16.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
NOCIL Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −6.5% latest against −2.4% at its 12-quarter best), ROCE holding at 4.0%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −6.5% | −6.9% | +7.1% | +6.2% |
| Profit | −45.6% | −27.8% | −8.6% | −3.3% |
| EPS | −45.9% | −28.1% | −8.9% | −3.7% |
| Share price | −9.0% | −8.5% | −8.9% | +11.2% |
4-Factor Sector Score
22.6/100 — rank 7 of 7 in Petrochem - Polymers · 96% evidence confidence
NOCIL Ltd scores 22.6 out of 100 against the 7 companies it is compared with in Petrochem - Polymers, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 5.5 + 5.3 + 8.8 + 3 = 22.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
NOCIL Ltd reported ₹330 Cr of revenue in the Mar 26 quarter, −2.9% year on year. Over 10 years it has compounded at 6.2% a year. The last full year, FY26, came in at ₹1,303 Cr. The last four reported quarters add to ₹1,303 Cr.
FY26 revenue came in at ₹1,303 Cr (−6.5% on the year), capping 10 years at 6.2% compound. The latest quarter (Mar 26) printed ₹330 Cr, −2.9% year on year.
Pace check: the last four quarters averaged −6.2% growth against the decade's 6.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −6.5% over the last 4 quarters against −5.0%/yr over the last 8 — stabilising; TTM profit −46.6% vs −35.7%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
NOCIL Ltd's operating margin is 6.0% in the Mar 26 quarter, −4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 8.0% to 28.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 6.0%, −4.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 8.0%–28.0%.
🚨 Why the margin moved: operating margin went −3.7 pp year on year while gross margin went −2.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
NOCIL Ltd earned ₹17.0 Cr of net profit in the Mar 26 quarter, −19.0% year on year. Full-year FY26 profit was ₹56.0 Cr. The 10-year compound rate is −3.3%. That is 5.2% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr.
Mar 26 profit was ₹17.0 Cr, −19.0% year on year. On the full year, FY26 printed ₹56.0 Cr (−45.6%), and the 10-year compound rate is −3.3%.
🚨 Why profit moved: revenue contributed −2.9% and the margin −4.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −39.6% vs revenue −6.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 164% of NOCIL Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹252 Cr of operating cash against ₹56.0 Cr of profit. After ₹192 Cr of capital spending, ₹60.0 Cr was left as free cash.
FY26: operating cash of ₹252 Cr against reported profit of ₹56.0 Cr, leaving free cash of ₹60.0 Cr after ₹192 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 164% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 164%: the cash cycle tightened 35 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 2.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
NOCIL Ltd's cash conversion cycle runs 84 days in FY26, down from 119 days in FY21. Capital spending ran ₹317 Cr over the last 3 years. At FY26 sales of ₹1,303 Cr each day of that cycle holds about ₹3.6 Cr, so roughly ₹300 Cr sits inside the business at any moment.
FY26: debtors at 81 days, inventory at 75 days — roughly 2.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 84 days, tighter than FY21's 119.
The full loop: cash goes out to suppliers and production on day 0; stock waits 75 days to sell; customers pay about 81 days after that; and suppliers themselves are paid at 72 days — netting out to the 84-day cycle.
In money terms: at FY26 sales of ₹1,303 Cr, each day of the cycle holds about ₹3.6 Cr — so the 84-day loop keeps roughly ₹300 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹317 Cr over the last 3 fiscal years against ₹162 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹221 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
NOCIL Ltd earns a ROCE of 4% in FY26. Return on invested capital clears the cost of that capital by −8.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 4.3% net margin on 0.62× asset turns.
FY26 ROCE is 4%.
🚨 Why the return is what it is — the wiring (FY26): 4.3% net margin × 0.62× asset turns × 1.19× balance-sheet leverage ≈ 3.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 3.1% − 12.0% = a −8.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
NOCIL Ltd carries total debt of ₹8.0 Cr against shareholder equity of ₹1,773 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹8.0 Cr against shareholder equity of ₹1,773 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 3.0 points of NOCIL Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 4.8% of the company. Domestic institutions moved +3.0 points over the same window, to 7.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −3.0 points over 8 quarters to 4.8%; Domestic institutions: +3.0 points over 8 quarters to 7.5%; Promoters: −0.1 points over 8 quarters to 33.8%.
Why the register moved: rotation — foreign institutions −3.0 points against domestic institutions +3.0 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
NOCIL Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bhansali Engineering Polymers LtdBEPL | 70.3/100Favorable setup87% evidence | TURNING | 21.5/35 Revenue 5.4% · PAT 15.6% · OPM change 0 pp 100% evidence | 17.9/25 ROCE 23.8% · OPM 17% 100% evidence | 15.9/20 P/E 14.4× · PEG 0.32 65% evidence | 15.0/20 RS sector 1.9% · RS bench 19.2% · 1Y 6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 21.5 + 17.9 + 15.9 + 15 = 70.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kothari Petrochemicals LtdKOTHARIPET | 65.6/100Favorable setup83% evidence | FADING | 17.7/35 Revenue 2.3% · PAT 12.3% · OPM change 1 pp 83% evidence | 21.4/25 ROCE 28.6% · OPM 16% 95% evidence | 13.2/20 P/E 11.3× · PEG — 50% evidence | 13.3/20 RS sector 1.3% · RS bench 4.4% · 1Y -17%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 21.4 + 13.2 + 13.3 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Supreme Petrochem LtdSPLPETRO | 64.0/100Mixed-positive evidence84% evidence | ASLEEP | 20.3/35 Revenue -2.1% · PAT 38.9% · OPM change 11 pp 95% evidence | 15.8/25 ROCE 17.6% · OPM 19% 95% evidence | 14.1/20 P/E 27.2× · PEG 0.73 65% evidence | 13.8/20 RS sector 29.5% · RS bench -0.8% · 1Y -10.9%2 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 15.8 + 14.1 + 13.8 = 64 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Manali Petrochemicals LtdMANALIPETC | 58.3/100Mixed-positive evidence76% evidence | BREAKING OUT | 23.1/35 Revenue 14.2% · PAT 100% · OPM change 0 pp 83% evidence | 9.1/25 ROCE 7.2% · OPM 9% 95% evidence | 10.3/20 P/E 15.7× · PEG — 15% evidence | 15.8/20 RS sector 1.5% · RS bench 4.5% · 1Y -11%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 9.1 + 10.3 + 15.8 = 58.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Styrenix Performance Materials LtdSTYRENIX | 48.1/100Mixed-negative evidence90% evidence | TURNING | 15.7/35 Revenue 15.3% · PAT -20.5% · OPM change 5 pp 88% evidence | 11.7/25 ROCE 15.1% · OPM 14% 100% evidence | 12.3/20 P/E 23.6× · PEG 1.68 100% evidence | 8.4/20 RS sector -9.6% · RS bench 9.8% · 1Y -19.1%8 of 11 weeks ahead 70% evidence |
| Exact sum: 15.7 + 11.7 + 12.3 + 8.4 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Chemplast Sanmar LtdCHEMPLASTS | 31.1/100Adverse evidence68% evidence | BASING | 16.3/35 Revenue -2.8% · PAT -80% · OPM change 11.8 pp 65% evidence | 4.8/25 ROCE 0.3% · OPM 15% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.0/20 RS sector -35.5% · RS bench -33.9% · 1Y -55.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 4.8 + 10 + 0 = 31.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7NOCIL Ltdthis pageNOCIL | 22.6/100Adverse evidence96% evidence | ASLEEP | 5.5/35 Revenue -6.5% · PAT -46.6% · OPM change -4 pp 88% evidence | 5.3/25 ROCE 3.9% · OPM 6% 100% evidence | 8.8/20 P/E 59.6× · PEG 0.97 100% evidence | 3.0/20 RS sector -5.4% · RS bench -2.3% · 1Y -11.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 5.5 + 5.3 + 8.8 + 3 = 22.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is NOCIL Ltd's share price today?
NOCIL Ltd trades at ₹164, −9.0% over the past year. The company is valued at ₹2,742 Cr. The stock sits at 60% of its 52-week range of ₹128–₹188, −2.7% versus its 200-day average. On the tape, the price is topping out, 3 weeks in. — as of 31 July 2026.
What were NOCIL Ltd's latest quarterly results?
NOCIL Ltd reported revenue of ₹330 Cr and net profit of ₹17.0 Cr for the Mar 26 quarter. Revenue fell 2.9% and profit fell 19.0% year on year. Earnings per share were ₹1.02. The operating margin was 6.0%, 4.0 pp lower than a year earlier. — as of 31 July 2026.
What is NOCIL Ltd's revenue?
NOCIL Ltd reported revenue of ₹330 Cr in the Mar 26 quarter, −2.9% year on year. For the full FY26 fiscal year, revenue was ₹1,303 Cr (−6.5%). Over the last 10 years revenue compounded at 6.2% a year. — as of 31 July 2026.
What is NOCIL Ltd's profit?
NOCIL Ltd earned ₹17.0 Cr of net profit in the Mar 26 quarter, −19.0% year on year. Full-year FY26 profit was ₹56.0 Cr. The operating margin ran 6.0% in the latest quarter. — as of 31 July 2026.
What is NOCIL Ltd's market cap?
NOCIL Ltd's market capitalisation is ₹2,742 Cr at a share price of ₹164. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is NOCIL Ltd's P/E ratio?
NOCIL Ltd trades at a P/E of 59.6×, at the 100th percentile of its own 10-year range, against a long-run median of 24.7×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does NOCIL Ltd pay a dividend?
Yes — NOCIL Ltd's dividend payout was 45% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is NOCIL Ltd overvalued?
On its own history, NOCIL Ltd looks expensive against its own history: its P/E of 59.6× sits at the 100th percentile of its 10-year range (long-run median 24.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is NOCIL Ltd growing?
Not right now — NOCIL Ltd's latest numbers are shrinking: latest-quarter revenue −2.9% year on year, profit −19.0%, and the margin −4.0 pp at 6.0%. The 10-year compound rates are 6.2% (revenue) and −3.3% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is NOCIL Ltd performing?
NOCIL Ltd is topping out, 3 weeks in. Its latest quarter's revenue fell 2.9% and profit fell 19.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is NOCIL Ltd in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −6.5% latest against −2.4% at its 12-quarter best), ROCE holding at 4.0%. The read comes from the last 12 quarters of growth (revenue growth −6.5% latest, profit growth −46.6% latest, eps growth −45.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is NOCIL Ltd in an uptrend?
It is stalling — the price is topping out (week 3 of stage 3), trading −2.7% versus its 200-day average and at 60% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is NOCIL Ltd beating the market?
Not lately — on a trailing-13-week view NOCIL Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +264% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will NOCIL Ltd's share price go up?
This page publishes no price forecast for NOCIL Ltd. What it measures instead: the share price is ₹164, the price is topping out 3 weeks in. Its P/E of 59.6× sits at the 100th percentile of its own 10-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns NOCIL Ltd?
Promoters hold 33.8% of NOCIL Ltd, foreign institutions 4.8%, domestic institutions 7.5% and the public 54.0% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 3.0 points over 8 quarters. — as of 31 July 2026.
Does NOCIL Ltd have too much debt?
No — NOCIL Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹8.0 Cr against equity of ₹1,773 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is NOCIL Ltd's capex?
NOCIL Ltd spent ₹317 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹192 Cr, with ₹221 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is NOCIL Ltd's cash flow?
NOCIL Ltd generated ₹252 Cr of operating cash flow in FY26 and ₹60.0 Cr of free cash flow after ₹192 Cr of capital spending. Reported profit that year was ₹56.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is NOCIL Ltd's profit real cash?
Yes — over the last 3 fiscal years, 164% of NOCIL Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹252 Cr against reported profit of ₹56.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is NOCIL Ltd in its business cycle?
NOCIL Ltd's FY26 operating margin was 8.0%, against a 13-year band of 8.0%–28.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 6.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the NOCIL Ltd story?
The sharpest disagreement: the price moved −9.0% in a year while annual EPS moved −45.9% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is NOCIL Ltd a stock worth studying right now?
This is not investment advice. The machine read: NOCIL Ltd's price has outrun its earnings. −9.0% in a year against EPS −45.9% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.